Burns Matteson Capital Management LLC Makes New Investment in Biogen Inc. $BIIB

Burns Matteson Capital Management LLC bought a new position in Biogen Inc. (NASDAQ:BIIB) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 3,919 shares of the biotechnology company’s stock, valued at approximately $690,000.

Other hedge funds have also recently made changes to their positions in the company. GoalVest Advisory LLC bought a new stake in Biogen during the fourth quarter worth approximately $35,000. Elevation Point Wealth Partners LLC bought a new stake in shares of Biogen in the 2nd quarter valued at approximately $25,000. Accredited Wealth Management LLC lifted its stake in shares of Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 185 shares during the last quarter. Elevation Wealth Partners LLC boosted its holdings in shares of Biogen by 412.8% in the 4th quarter. Elevation Wealth Partners LLC now owns 200 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 161 shares during the period. Finally, True Wealth Design LLC increased its position in shares of Biogen by 62.9% during the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 90 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. This represents a 24.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.18% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms recently weighed in on BIIB. Morgan Stanley set a $190.00 price target on Biogen in a report on Sunday, February 8th. Oppenheimer boosted their price objective on shares of Biogen from $205.00 to $225.00 and gave the company an “outperform” rating in a research report on Friday, January 30th. HC Wainwright increased their target price on shares of Biogen from $194.00 to $228.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Guggenheim lifted their price target on shares of Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, HSBC upped their price target on shares of Biogen from $143.00 to $150.00 and gave the company a “reduce” rating in a report on Tuesday, March 17th. Twelve equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $205.31.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: FDA approves a higher‑dose regimen of SPINRAZA, which could bolster Biogen’s rare‑disease revenue and defend market share in spinal muscular atrophy; the approval was cited as a catalyst for an earlier share pop. US FDA approves higher-dose of Biogen’s genetic disorder drug
• Positive Sentiment: Biogen agreed to buy Apellis for about $5.6B, gaining commercial drugs (EMPAVELI®, SYFOVRE®) and entry into nephrology and ophthalmology — a strategic move to diversify beyond MS and lift long‑term growth expectations. Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio
• Neutral Sentiment: Analysts largely kept Hold/neutral ratings after the news — firms note the approvals and deal are constructive but that execution, MS franchise erosion and competition limit near‑term upside. Spinraza HD approval supports but does not transform outlook
• Negative Sentiment: Market reaction is mixed-to-negative for BIIB: Apellis stock more than doubled on the buyout (market sees strong value in Apellis), while Biogen shares fell as investors weigh the $5.6B cash outlay, premium paid and contingent CVR payments. Apellis Pharma Skyrockets on Biogen Deal
• Negative Sentiment: Integration and financial risk: analysts and commentary flag potential near‑term pressure on cash and the need to execute launches and cross‑sell acquired products; some view the price as a premium that constrains near‑term EPS benefit. Biogen Acquires Apellis: Synergies, Risks, And What The Market Is Missing

Biogen Stock Performance

BIIB stock opened at $183.33 on Wednesday. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $202.41. The firm has a market cap of $26.91 billion, a price-to-earnings ratio of 20.81, a PEG ratio of 1.49 and a beta of 0.15. The business’s fifty day simple moving average is $186.19 and its two-hundred day simple moving average is $170.98. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last issued its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The firm had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business’s revenue was down 7.2% on a year-over-year basis. During the same period in the previous year, the firm earned $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Analysts predict that Biogen Inc. will post 15.83 earnings per share for the current year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.